Reduction in fear of hypoglycemia in subjects with sub-optimally controlled diabetes using a glargine insulin-based treatment regimen

Canadian Journal of Diabetes

Volumn 32, Issue 2, 2008, Pages 101-106

  Gilbert, Richard E ^a,b   Fulcher, Greg ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Anxiety depression; Basal insulin analogues; Fear of hypoglycemia; Insulin glargine

Indexed keywords

GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN GLARGINE;

ADULT; ANTICIPATORY ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REGIMEN; FEAR; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURNAL HYPOGLYCEMIA;

EID: 45849143587     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-2671(08)90000-9     Document Type: Article

References (14)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
3. Cryer PE. Hypoglycemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45:937-948.
4. Pramming S, Thorsteinsson B, Bendtson I, et al. Symptomatic hypoglycemia in 411 type 1 diabetic patients. Diabet Med. 1991;8:217-222.
5. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
6. Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950-955.
7. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med. 2004;21:1213-1220.
8. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282-1288.
9. Irvine AA, Cox D, Gonder-Frederick L. Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychol. 1992;11:135-138.
10. Cox DJ, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care. 1987;10:617-621.
11. Ebos JM, Tran J, Master A, et al. Imatinib mesylate (STI-571) reduces BCR-ABL-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res. 2002;1:89-95.
12. Peyrot M, Rubin RR. Levels and risks of depression and anxiety symptomatology among diabetic adults. Diabetes Care. 1997;20:585-590.
13. Gary TL, Crum RM, Cooper-Patrick L, et al. Depressive symptoms and metabolic control in African-Americans with type 2 diabetes. Diabetes Care. 2000;23:23-29.
14. Lloyd CE, Dyer PH, Lancashire RJ, et al. Association between stress and glycemic control in adults with type 1 (insulin-dependent) diabetes. Diabetes Care. 1999;22:1278-1283.